A new study involving 97 patients with advanced, treatment-resistant multiple myeloma has shown a remarkable response to a last-resort immunotherapy developed by Legend Biotech. In this study, one-third of the patients responded positively to the treatment, with their cancer disappearing completely and not returning after five years – an unprecedented outcome in this incurable disease. The results have prompted some oncologists to suggest the possibility of a “potential cure” for multiple myeloma.
The study, funded by Johnson & Johnson, was presented at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology. Legend Biotech’s shares rose 4.4% to $29.68 after the news broke.
Source: https://www.tipranks.com/news/the-fly/legend-immunotherapy-offers-hope-of-cure-for-incurable-blood-cancer-nyt-says-thefly